AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Over the past decade, AbbVie's shares have increased by 353.3%, or 16.3% annually, with dividends reinvested. That's ...

Q2 2025 Earnings Call Transcript July 31, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.97, expectations were $2.88. Operator: Good morning, and thank you for standing by. Welcome ...

AbbVie Inc. (NYSE:ABBV) is a research-driven biopharmaceutical company that discovers and delivers innovative medicines and ...

AbbVie and Genmab’s epcoritamab has shown promise as part of a combination treatment for relapsed or refractory follicular ...

Shares of AbbVie Inc. ABBV rose 1.42% to $201.47 Wednesday, on what proved to be an all-around positive trading session for ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

This was the stock's second consecutive day of gains.

Go Higher. AbbVie’s anti-inflammatory drug Humira was never cheap, selling for about $19,000 a year in 2012. It’s gone up by 100 percent since then. By Danny Hakim ...

Go Higher. AbbVie’s anti-inflammatory drug Humira was never cheap, selling for about $19,000 a year in 2012. It’s gone up by 100 percent since then. By Danny Hakim ...